Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)

NCT02935712 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Male Subjects With Type II Diabetes (T2DM)

Interventions

DRUG: AZD8601+Placebo (SAD)
DRUG: AZD8601+Placebo
DRUG: Placebo+Placebo

Sponsor

AstraZeneca

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]